MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2026 International Congress

October 4-8, 2026. Seoul, Korea.

View by Title View Categories
Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z
  • Iatrogenic akathisia aggravating depressive and psychotic symptoms: a case report

    A. Katok, D. Khasanova (Kazan, Russian Federation)

  • Icariin, a Flavonoid from Epimedium, Confers Dopaminergic Neuroprotection and Neuromodulation in MPTP-Induced Parkinsonian Rats

    A. Singh (Allahabad, India)

  • Identification of a Novel MYORG Mutation in Autosomal Recessive Idiopathic Basal Ganglia Calcification-7 (IBGC7): A Case Report

    W. Kamel, D. Al Mehatab, L. Bastaki (Beni-Suef, Egypt)

  • Identification of a sporadic dystonia-related brain network using resting-state fMRI and machine learning

    O. Omilabu, D. Truong, K. Nguyen, S. Vacca, T. Fitzpatrick, A. Oh, M. Neithammer, N. Nguyen, D. Eidelberg, A. Vo (Great Neck, USA)

  • Identification of Alpha-synuclein Pathology in Dementia with Lewy Body Participants by Seed Amplification Assay

    C. Farris, S. Weber, Y. Ma, M. Starke, B. Mollenhauer, L. Concha (Kassel, Germany)

  • Identification of Alpha-synuclein Pathology in Idiopathic Rapid Eye Movement Sleep Disorder Participants by Seed Amplification Assay

    C. Farris, S. Weber, Y. Ma, M. Starke, B. Mollenhauer, L. Concha (San Diego, USA)

  • Identification of Alpha-synuclein Pathology in Primary Tauopathies by Seed Amplification Assay

    C. Farris, S. Weber, Y. Ma, M. Starke, D. Irwin, A. Siderowf, B. Mollenhauer, L. Concha (Kassel, Germany)

  • Identification of Candidate Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Using Mass Spectrometry‑Based Proteomics in CSF Biobank Samples

    P. Kallunki, M. Lubas, J. Fussing Tengberg, V. Carmelo, S. Virreira Winter, P. Geyer (Valby, Denmark)

  • Identification of DAGLB Variants in Chinese Patients With Early-Onset Parkinson’s Disease

    W. Ren, J. Huang, Y. Guan, W. Zhao, Y. Guo, R. Hua, H. Liu (Changsha, China)

  • Identification of Digital Measures of Motor Progression from In-Clinic Assessments in Early Parkinson’s Disease for Composite Digital Biomarkers: Results from WATCH-PD

    J. Ren, S. Zhai, J. Shen, O. Patil, R. Baumgartner, ER. Dorsey, J. Adams, D. Mehrotra, M. Dockendorf (Rahway, USA)

  • Identification of Discriminative Odorants for Parkinson’s Disease and Their Clinical Correlates: A Population-Specific Short-Form Approach

    YH. Lin, TC. Fang, MH. Chang, YJ. Guo (Taichung, Taiwan)

  • Identification of Novel FA2H Mutations in Patients with Hereditary Spastic Paraplegia Type 35 (SPG35)

    L. Wang, X. Jin, W. Luo (Hangzhou, China)

  • Identification of Parkinson’s Disease Tremor-Related Functional Network Topographies Using 3.0 T rs-fMRI

    ZY. Lin, J. Li, ZT. Zeng, DY. Li (Lanzhou, China)

  • Identification of Phenotypes in a Prospective Parkinson’s Disease Cohort Using Digital Wearable Monitoring

    A. Saenz, I. Gabilondo, S. Seijo, A. Ochoa, U. Zalabarria, I. Cuenca, B. Tijero, T. Fernández, M. Ruiz, M. Acera, J. Gomez, R. Del Pino (Barakaldo, Spain)

  • Identifying Informative Speech Tasks for Detecting Clinically Relevant Changes in Parkinson’s Disease

    T. Thies, I. Rubi-Fessen, J. Strelow, J. Tröger, D. Mücke, M. Barbe (Cologne, Germany)

  • Identifying Parkinson’s Disease Subtypes Using Fluid Biomarkers Clustering in the PPMI Cohort

    C. Mcintyre, N. Maki, J. Li, J. Ruiz Tejeda, R. Rajmohan, N. Phielipp (Chicago, USA)

  • Identifying Peripheral Stimulation Sites to Treat Parkinson’s Disease Gait Impairments

    N. Hennessy, M. Bravo, J. Fallon, M. Shoushtarian (East Melbourne, Australia)

  • Image-Guided DBS Programming in Dystonia: Experience from a Tertiary Public Brazilian Center

    M. Soares, J. Nogueira, J. Gomes, M. Bezerra (Recife, Brazil)

  • Immigration status and Parkinson’s disease: a retrospective matched cohort study

    A. Peral Quirós, N. Caballol Pons, P. Lombardo, A. Planas Ballvé, MI. Gómez-Ruiz, A. ávila Rivera (Sant Joan Despí, Spain)

  • Immune-mediated Chorea in Antiphospholipid Syndrome: Normalization of FDG-PET and Neurofilament as Markers of Treatment Response.

    L. Peraferrer-Montesinos, J. Martínez-Rodríguez, A. Fernández-Lebrero, M. Viles-Garcia, E. Carrillo Villamizar, P. Plaza-López, V. Puente-Periz, I. Navalpotro-Gómez (Barcelona, Spain)

  • Immunological characteristics of Parkinson’s disease by clinical form and stage

    S. Jumanazarova, E. Abduqodirov, R. Matmurodov, S. Mamatova (Tashkent, Uzbekistan)

  • Immunological principles of levodopa therapy in Parkinson’s disease

    N. Naimov, B. Muminov, S. Jumanazarova, R. Matmurodov, H. Daminova (Tashkent, Uzbekistan)

  • Impact of a Structured Patient Education Module on Knowledge of Botulinum Toxin Therapy, Goal Attainment, and Treatment Satisfaction in Cervical Dystonia

    K. Katawatee, R. Bhidayasiri, P. Panyakaew (Bangkok, Thailand)

  • Impact of Alpha-Synuclein Burden and Cellular Stress on GBA-PD Macrophage

    V. Lentini, G. Uras, D. Moreno-Martinez, S. Lucas, A. Pantaleo, D. Hughes (London, United Kingdom)

  • Impact of Amyloid-beta co-pathology on future hallucination in Parkinson’s disease

    M. Park (Gwangmyeong, Republic of Korea)

  • Impact of Caffeine Consumption on Clinical Phenotype and Non-Motor Symptoms in Parkinson’s Disease

    A. Rekik, M. Abid, R. Guizani, K. Jemai, A. Mili, H. Slimene, A. Hassine, S. Naija, S. Ben Amor (Sousse, Tunisia)

  • Impact of Comorbidities on Clinical Outcomes and Socioeconomic Burden in Parkinson’s Disease: A 10-Year Nationwide Cohort Study

    JS. Park, HT. Kim (Busan, Republic of Korea)

  • Impact of Continuous Subcutaneous Foslevodopa/Foscarbidopa (FLC/FCD) on Non-Motor Symptom Burden in Advanced Parkinson’s Disease: Domain-Level Analysis

    K. Waqar, M. Thomas, Y. Abdelmajid, E. Freitas, R. Cabrito, RH. Battah, A. Anjum, SH. Mittal (Abu Dhabi, United Arab Emirates)

  • Impact of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion on Neuropsychiatric Symptoms in Clinical Practice: A Multicenter Study

    D. Campo-Caballero, J. Rodríguez-Antigüedad, A. Puig-Davi, J. Ruiz-Martinez, A. Vinagre-Aragón, E. Mondragón, L. Pardina, G. González-Ortega, D. Santos-García (San Sebastian, Spain)

  • Impact of foslevodopa/foscarbidopa infusion on autonomic symptoms in advanced Parkinson’s Disease

    D. Rinaldi, L. de Carolis, E. Bianchini, S. Galli, M. Salvetti (Rome, Italy)

  • Impact of Helicobacter pylori Eradication on MDS-UPDRS Part III Motor Score in Patients With Parkinson’s Disease A Prospective Cohort Study in Northern Mexico

    S. Murillo Quintana, D. Sanchez Galvan (Torreon, Mexico)

  • Impact of Hula on Balance Outcomes in Parkinson’s Disease

    M. Yee, P. Young, R. Shuman, C. Stickley, M. Bruno (Honolulu, USA)

  • Impact of Multi-day Wearable Monitoring on Neurologists’ Assessment of Motor Fluctuations and Treatment Strategies in Parkinson’s Disease: A Real-World Study

    M. Borrell-Pichot, L. Pérez-Carasol, A. Campolongo, B. Pascual-Sedano, R. Martínez-Fernández, JA. Aibar-Rodríguez, J. Kulisevsky, I. Aracli-Bolaños (Barcelona, Spain)

  • Impact of Symptom-Specific Odorants on the Diagnostic Accuracy of Brief Olfactory Tests in Parkinson’s Disease

    TC. Fang, YH. Lin, MH. Chang, YJ. Guo (Taichung, Taiwan)

  • Impact of TRPV4 Deletion on Nociception in an Experimental Model of Parkinson’s Disease Non-Motor Symptoms

    L. Gomes Pereira, K. Casali Vieira, C. David Antoniazzi, G. Trevisan (Santa Maria, Brazil)

  • Impact of Variants in ADH1B and ALDH2 on Parkinson’s Disease in Japan

    M. Kinoshita, H. Ohara, R. Sasaki, K. Tamura, M. Iyer, B. Vellingiri (Kyoto, Japan)

  • Impact of Vitamin D Supplementation on Cognitive Function, Quality of Life, and Dyskinesia in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    C. Perera, A. Pathirage, K. Muhunthan, S. Jayakody, C. Arambepola, T. Chang (Colombo, Sri Lanka)

  • Impaired Cortical Compensation in GBA1-Associated Parkinson’s Disease

    K. Steidel, M. Johansson, B. Bloem, L. Pavelka, T. Lüth, C. Pauly, E. Soboleva, S. Jónsdóttir, C. Much, S. Schaake, L. Vilas Boas, E. Thiry, G. Zelimkhanov, N. Brüggemann, C. Klein, J. Trinh, R. Krüger, R. Helmich (Nijmegen, Netherlands)

  • Impaired Retention of Goal-Directed Movements in Parkinson’s Disease: A 2-Year Longitudinal Analysis

    JJ. Kim, S. Delmas, ER. Tobin, RJ. Malik, VR. Shankar, AMA. Chagas, TW. Worthington, JH. Lee, B. Yacoubi, DE. Vaillancourt, EA. Christou (Gainesville, USA)

  • Implementation and Evaluation of a Pre-Clinic Questionnaire to Improve Data Capture and Consultation Efficiency in Parkinson’s Disease Clinics: A Multi-Centre Pilot Study

    M. Qamar, H. Martin, J. Price, M. Parry (London, United Kingdom)

  • Implementation of a Hindi REDCap Instrument for the Unified Parkinson’s Disease Rating Scale (UPDRS)

    A. Elavarasi, T. Mestre (Delhi, India)

  • Implementing Adaptive Deep Brain Stimulation in Parkinson’s Disease: A Multimodal Mixed-Methods Evaluation of a Pragmatic Clinical Workflow

    A. Whone, T. Chimonas, G. Leogrande, A. Holt-Becker, R. Raike, R. Ashida, K. O'Hara (Bristol, United Kingdom)

  • Improved “Good On” Time and Reduced Motor Fluctuations After Switching to IPX203: Interim Real-World Results from the First 111 Patients in ELEVATE PD

    R. Hauser, S. Isaacson, S. Betté, A. Richmond, M. Jay, G. Banisadr, S. Fisher, H. Visser (Tampa, USA)

  • Improvement in Time Spent in OFF State and In the Functional Impact of Motor Fluctuations After Initiation with COMT Inhibitors in Parkinson’s Disease Patients with Early Wearing-Off: Results from the REONPARK Study

    L. López-Manzanares, B. Solano, T. Delgado, J. García-Caldentey, A. Rodriguez-Sanz, R. García-Ramos, M. Rodriguez-de Miguel, I. Tegel, D. Magalhāes, J. Holenz (Girona, Spain)

  • Improvement of Pseudobulbar Affect in Progressive Supranuclear Palsy with Amantadine: A Case Report

    B. Daud Shah, J. Reding, E. Noyes, A. Rajput (Saskatoon, Canada)

  • Improvement of Wearing‑Off Symptoms After Initiation of COMT Inhibitors in Parkinson’s Disease patients with early motor fluctuations: Results from the 12 months interim analysis of REONPARK Study

    L. López-Manzanares, M. Cerdán, I. Gaston, R. Vázquez, B. Vives, M. Carmona, M. Rodriguez-de Miguel, I. Tegel, D. Magalhāes, J. Holenz (Madrid, Spain)

  • Improving Community Access to Parkinson’s Disease Clinical Trials: Protocol for a Regional Navigation Toolkit in Southern California

    A. Singh, J. Adrissi, A. Mendizabal, D. Lim, A. Shurlock, D. Thordarson (Los Angeles, USA)

  • Improving Equitable Access to Parkinson’s Disease Exercise Programs Through a Student-Led Transportation Model

    S. Bhagwagar, J. Dempsey, J. Meyer, T. Chabrashvili (Syracuse, USA)

  • Impulse Control in Parkinson’s: β- and Muscle Burst Dynamics Reveal Distinct Effects of Pathology and Dopamine Medication

    A. Warden, D. Cruse, C. Mcallister, B. Wright, H. Macdonald (Birmingham, United Kingdom)

  • Impulse-compulsive disorders and non-motor symptom profiles in Parkinson’s disease: findings from a Tunisian cohort

    E. Cherif, A. Rekik, A. Mili, K. Jemai, A. Hsini, H. Slimen, S. Naija, A. Hassine, S. Ben Amor (Sousse, Tunisia)

  • IMU Insole-Derived Gait Digital Biomarkers in idiopathic RBD and Parkinson Disease

    JH. Jung, M. Son, J. Jeon, SY. Kang, PH. Lee, SJ. Kim (Busan, Republic of Korea)

  • In Silico Investigation of Dopamine Receptor–Calcium Channel Coupling in Subthalamic Nucleus Neurons: Implications for Parkinson’s Disease Therapy

    A. Pradhan (Bangalore, India)

  • In Vivo 18F-Florzolotau Tau PET Imaging in Parkinson’s Disease with and without Probable REM Sleep Behavior Disorder

    C. Xu, Y. Tang, J. Wang (Shanghai, China)

  • Incidence and movement disorders associated with Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT) in the Princess Maha Chakri Sirindhorn Medical Center (MSMC)

    K. Methawasin, N. Suthumchai, N. Wangwiwatcharoen, K. Anuroj (Nakhon Nayok, Thailand)

  • Incidence and Outcomes of Hip Fractures in Parkinsonism vs Non-Parkinson Population: A Systematic Review of the Literature

    U. Saini (Chandigarh, India)

  • Incisionless versus Implantable: A Comparative Systematic Review of Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Thalamotomy versus Deep Brain Stimulation in Tremor-Dominant Parkinson’s Disease: Long-Term Durability and Safety Outcomes

    A. Al-Zaidi, F. Al-Zaidi, Z. Hussein (Salahddin, Iraq)

  • IncobotulinumtoxinA for the Treatment of Lower Limb Spasticity in Children and Adolescents with Cerebral Palsy Evaluation of Lower Limb IncobotulinumtoxinA Efficacy (ELLIE)

    I. Makedonska (Dnipro, Ukraine)

  • IncobotulinumtoxinA to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 7-year Interim Results

    B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, G. Pollet, M. van Zandijcke (Bruges, Belgium)

  • Increased Pre-Alpha EEG Functional Connectivity Forecasts Future Cognitive Decline in Parkinson’s Disease

    A. Tetereva, G. Hall-Mcmaster, N. Slater, A. Harris, R. Shoorangiz, C. Le Heron, R. Keenan, I. Kirk, W. Meissner, T. Anderson, T. Melzer, N. Pat, J. Dalrymple-Alford (Christchurch, New Zealand)

  • Influence of Disease Duration on Motor Progression in Parkinson’s Disease: A Longitudinal Cohort Study with Age at Onset Stratification and Sensitivity Analysis

    N. Babu, S. Prasad, T. Nagaraj, S. Bhat, M. Bhardwaj, SS. Aramugham, K. Kumar, R. Mahale, P. Mailankody, V. Holla, N. Kamble, R. Yadav, P. Pal (Bengaluru, India)

  • Influence of disease stage upon real-world turning performance in people with Parkinson’s

    C. Wilkinson, S. Del Din, C. Schlenstedt, C. Becker, J. Buekers, B. Caulfield, L. Delgado, J. Garcia-Aymerich, H. Gassner, A. Nieuwboer, J. Hausdorff, A. Mirelman, L. Rochester, W. Maetzler, A. Yarnall, L. Alcock (Newcastle-upon-Tyne, United Kingdom)

  • Inpatient Titration Protocol and Practical Implementation of Continuous Subcutaneous Foslevodopa/Foscarbidopa: Lessons from 28 Consecutive Cases

    Y. Abdelmajid, M. Thomas, K. Waqar, E. de Freitas, R. Cabrito, R. Battah, A. Anjum, S. Mittal (Abu Dhabi, United Arab Emirates)

  • Insight into α-synuclein pathogenicity by a human cell model with suppressed NatB-mediated N-terminal acetylation

    A. Caiella, E. Timmerman, M. Lundekvam, N. Glomnes, T. Hjellvoll, F. Impens, H. Aksnes, T. Arnesen (Bergen, Norway)

  • Insights on the Groaning Phenomenon from a Large Asian Progressive Supranuclear Palsy Cohort

    TQ. Lim, LY. Tan, KN. Chen, WP. Lim, YX. Tee, A. Lee, WY. Tee, SY. Wong, YZ. Lim, JC. Fernandiz, AN. Khairul Anuar, KS. Lim, YW. Tay, TS. Toh, HX. Ding, WH. Han, C. Ganos, AH. Tan, SY. Lim (Kuala Lumpur, Malaysia)

  • Integrated and Multidisciplinary Care for Older Adults with Parkinson’s Disease: A value-driven approach

    P. Venugopalan Menon, M. Tan, W. Hong, E. Gondo Santoso, S. Kumari, A. Soh, S. Kumar Seetharaman (Singapore, Singapore)

  • Integrated Digital Monitoring and Outpatient Clinical Care Management Program for Parkinson Disease

    S. Shaffer, A. Hare, M. Anderson, M. Dauer, S. Grant, T. Jansen, J. Aldred, R. Gilron (Spokane, USA)

  • Integrating Multidisciplinary, Family-Centered Care to Optimize Functional Outcomes in Children with Cerebral Palsy.

    T. Voloshyn (TRUSKAVETS, Ukraine)

  • Integrating Olink Proteomics and Multimodal MRI to Reveal a Multimodal Signature of Parkinson’s Disease with REM Sleep Behavior Disorder

    LH. Zhu, F. Wang, YY. Zhu, KF. Yin, CX. Liu, LF. Yang, Q. Cui, WN. Xiong, YB. Han, AL. Pang, XL. Yang (kunming, China)

  • Integrating Psychology into a Parkinson’s Disease Service – Evaluating Need

    R. Lewis-Morton, O. Batterbee, T. Edwards, B. Mohamed, J. Adenwalla (Cardiff, United Kingdom)

  • Integrating Transcriptomics and Morphological Profiling to Characterize GBA-Associated Parkinson’s Disease in Midbrain Organoids

    F. Nasta, E. Glaab, JC. Schwamborn (Esch-sur Alzette, Luxembourg)

  • Integrative Analysis of GBA1 Mutations and GCase Deficiency in Parkinson’s Disease using Long Read Nanopore Sequencing

    A. Shaikh, S. Prakash, R. Valmiki (Vellore, India)

  • Inter-Rater Variability in Motor Assessment Scoring: Measurement Implications for Understanding Movement Disorders in Aging

    R. Singh, E. Nishat, R. Nasir, B. Bridges (St John's, Canada)

  • Interaction Between Physical and Cognitive Function That Determines ADL Improvement in Hospitalized Patients with Parkinson’s Disease: Implications for Individualized Rehabilitation Strategies

    R. Nakagawa, M. Shiraishi, N. Takao, H. Matsumoto, Y. Yamano (Kawasaki City, Kanagawa Prefecture, Japan)

  • Interest in Clinical Trial Participation in Parkinson’s Disease: Insights from a Nationwide Registry

    M. Peball, B. Heim, A. Djamshidian, F. Krismer, R. Katzenschlager, P. Schwingenschuh, W. Pirker, W. Poewe, K. Seppi (Innsbruck, Austria)

  • Interleaving Deep Brain Stimulation: Achieving Optimal Clinical Outcomes at Lower Per-contact Voltages and Energy Consumption

    CY. Por, TT. Lim, O. Phokaewvarangkul, R. Bhidayasiri (Kuching, Malaysia)

  • Interleukin 6 in the assessment of Parkinson’s disease and Progressive Supranuclear Palsy

    N. Madetko-Alster, M. Markiewicz, P. Chunowski, P. Alster (Warsaw, Poland)

  • International validation of the Neuropsychiatric Fluctuations Scale in patients with Parkinson’s disease

    I. Debove, C. Rodriguez-Blazquez, A. Zenger, A. Ayala, M. Bereau, S. Bostantjopoulou, KR. Chaudhuri, MA. Qamar, E. Cubo, B. Falkenburger, C. Falup-Pecurariu, MJ. Forjaz, MM. Kurtis, H. Reichmann, P. Krack, P. Martinez-Martin (Bern, Switzerland)

  • International, multicenter validation study of the Shame in Parkinson’s disease (SPARK) Scale

    C. Rodriguez-Blazquez, I. Debove, A. Ayala, V. Fleury, A. Zenger, M. Kurtis, E. Cubo, C. Falup-Pecurariu, KR. Chaudhuri, MA. Qamar, H. Reichmann, S. Bostantjopoulou, M. Bereau, MJ. Forjaz, P. Martinez-Martin, P. Krack (Madrid, Spain)

  • Interplay of sex and GBA1 and LRRK2 genotype in Parkinson disease progression

    J. Park, M. Yang, N. Masood, R. Ortega, D. Raymond, A. Wise, B. Green, K. Leaver, V. Katsnelson, V. Shanker, M. Swan, M. Pullman, A. Domingo, L. Ozelius, S. Bressman, C. Wang, R. Saunders-Pullman (New York, USA)

  • Interpretable AI for Quantitative Video-Based UPDRS Assessment of Hand Movements in Parkinson’s Disease

    A. Irani, A. Mehrani, A. Soltani Mohammadi, K. Park, M. Mirian, R. Hosseini, H. Moradi, M. Mckeown (Tehran, Islamic Republic of Iran)

  • Intersectin-1 (ITSN1) Loss-of-Function Variants in Parkinson’s Disease: Clinical Phenotypes and Neuropathological Insights

    J. Frost, O. Serrano Asensio, J. Ooi, YK. Chia, S. Lim, Y. Tay, C. Lin, A. Robinson, C. Kobylecki, A. Tan, K. Kurian, C. Smith, D. Grosset, L. Parkkinen, Z. Jaunmuktane, T. Warner, C. Blauwendraat, R. Real, H. Morris, GP2. Consortium (London, United Kingdom)

  • Interventions in Friedreich’s Ataxia and their Influence on Patient-centric Outcomes: A Systematic Review

    D. Sarwinska, M. Buchholz, A. Iskandar, M. Grobe-Einsler, T. Klockgether, J. Faber, B. Michalowsky (Greifswald, Germany)

  • Intestinal Dysbiosis in Parkinson’s Disease: Mechanisms, Clinical Implications, and Therapeutic Perspectives (2015–2025)

    H. Harifi (Kenitra, Morocco)

  • Intestinal Levodopa Infusion Therapies in Advanced Parkinson’s Disease: A 6-Month Prospective Cohort Study

    I. Straka, Z. Andre, S. Bilek, P. Valkovic, Z. Kosutzka, M. Minar (Bratislava, Slovakia)

  • Intra-familial phenotypic variability in a novel Autosomal dominant GCH1 variant

    W. Kamel, D. Al Mehatab, M. Mohamed Ibrahim, L. Bastaki (Beni-Suef, Egypt)

  • Intrafamilial Phenotypic Diversity Associated with Coexisting LRRK2 G2385R and a Novel GCH1 Variant: A Case Report

    CE. Wang, YF. Sung (Taipei, Taiwan)

  • Intranasal Delivery of Berberine-Loaded Solid Lipid Nanoparticles Ameliorates Neuropathological and Behavioral Deficits in a Preclinical Alzheimer’s Model

    R. Rajput, V. Sharma (New Delhi, India)

  • Intranasal spray for nose-to-brain drug delivery: Emergency treatment of OFF episodes in Parkinson’s disease

    Y. Tang, X. Yue, E. Liang, C. Wu (Guangzhou, China)

  • Intravenous AAVrh.10hFXN (LX2006) Gene Therapy in Friedreich Ataxia: Early Neurologic Assessment from Two Phase 1 and 2 Studies

    T. Zesiewicz, T. Vu, J. Weinsalft, S. Kaminsky, A. Patel, R. Gavrilova, S. Perlman, U. Krishnan, M. Galbraith, N. Savage, R. Kaner, M. Vo, H. Sarva, A. Yoo, D. Sondhi, C. Rummey, G. Aubert, A. Khan, S. Ghanekar, R. Crystal (Tampa, USA)

  • Intrinsic Suppression of the NRF2–Ferroptosis Defense Axis Defines Selective Vulnerability of D2-Striosome Neurons in Huntington’s Disease

    LY. Lu, ZQ. Chen, Y. Huang (Beijing, China)

  • Investigating Cerebellar Network Alterations in Musician’s Dystonia

    N. Nasrkhani, A. Bhattacharya, R. Chen (Toronto, Canada)

  • Investigating Hippocampal Subfield and Amygdala Volumes in Parkinson’s Disease with Anxiety

    Y. Feuozi, C. Lambert, G. Sheehan, C. Dore, A. Schrag (London, United Kingdom)

  • Investigating Mitochondrial Integrity in Spinocerebellar Ataxia Type 12 via Patient-Derived iPSC Models

    J. Rungta, R. Banerjee, S. Sengupta, B. Reddy, S. Ansari, R. Khatun, J. Ganguly, D. Dutta, S. Mukherjee, P. Basu, S. Choudhury, R. Pal, S. Chattarji, H. Kumar (Kolkata, India)

  • Investigating Phospho-α-Synuclein Pathology in Patient-Specific Microglia Integrated into Midbrain Organoids

    E. Zuccoli, H. Kurniawan, JC. Schwamborn (Esch-sur Alzette, Luxembourg)

  • Investigating Plasma SIRT3 and SYT11 as Potential Indicators in Parkinson’s Disease: A Preliminary Exploratory Study

    Y. Deng, H. Cao, Q. Qu, Y. Wang (Xi'an, Shaanxi Province, China)

  • Investigating Smiling Asymmetries in Parkinson’s Disease through the Whistle–Smile Reflex

    M. de Riggi, A. Martini, G. Paparella, D. Birreci, S. Aloisio, AS. Grandolfo, L. Angelini, D. Costa, L. Marsili, M. Bologna (Rome, Italy)

  • Investigating Substantia Nigra Microstructural Integrity as a Potential Predictive Biomarker for Fall Burden in Parkinson’s Disease

    I. Bedoy, J. Tejeda, R. Rajmohan, N. Phielipp (Irvine, USA)

  • Investigating Subthalamic Neuronal Activity in Parkinsonian Patients with Hemidystonia

    P. Pavlovsky, A. Golik, A. Gamaleya, A. Tomskiy, A. Sedov, E. Belova (Moscow, Russian Federation)

  • Investigating the Causal Relationship Between Tofu Intake and Parkinson’s Disease in the Asian Population Using Mendelian Randomization

    X. Guo, R. Li (Xi'an, China)

  • Investigating the Genetic Effect of GALC in Parkinson’s Disease

    M. Ghamgosar Shahkhali, T. Durcan, Z. Gan-Or (Montreal, Canada)

  • Investigating the Link Between Alzheimer’s Disease Genetic Risk Variants and Parkinson’s Disease Cognitive Impairment: An Exploration of Genetic Overlap

    A. Zirra, S. Jasaityte, P. Dimartino, A. Deoliveira Franco, R. Torricelli, J. Kenny, I. Nakashidze, M. Mshvenieridze, S. Sopromadze, V. van Midden, L. Gilchrist, P. Proitsi, A. Noyce, M. Perinan (London, United Kingdom)

  • Investigating the role of ATP7B heterozygous variants in Parkinson’s Disease

    P. Mitrotti, M. Avenali, P. Dimartino, R. Minardi, G. Pisano, I. Palmieri, A. Fiorentino, L. Malfer, M. Khani, P. Reyes, G. Cossu, V. Carelli, EM. Valente (Pavia, Italy)

  • Investigating the Role of Biallelic EPG5 Variants in Parkinson’s Disease

    R. Torricelli, G. Cogan, B. Bustos, C. Tesson, T. Abramova, I. Keller Sarmiento, A. Hejnusova, V. Quintana Pena, A. Tan, T. Ong, S. Lim, H. Morris, J. Frost, C. Pinon, S. Lesage, A. Noyce, M. Periñan, J. Trinh, A. Brice, N. Mencacci (London, United Kingdom)

  • Investigation of Sex-based Differences in the Utility of IgG Index as a Potential Predictor of Cognitive Impairment in Parkinson’s Disease

    R. Edillor, J. Ruiz-Tejeda, R. Rajmohan, N. Phielipp (Irvine, USA)

  • Investigation of the Mendelian contribution of parkinsonism associated genes to Parkinson’s disease

    G. Cogan, K. Rousvoal, C. Tesson, L. Arnaud, A. Méneret, G. Mangone, S. Sambin, G. Kodjovi, A. Lanore, E. Leguern, J. Corvol, S. Lesage, A. Brice (Paris, France)

  • Ion Channel Modulation by Dopamine Receptors in Subthalamic Nucleus Neurons: Implications for Parkinson’s Disease Pathophysiology

    C. Mahapatra (Pessac, France)

  • Ipsilateral chorea due to thalamic hemorrhage: insights into network mechanisms of post-stroke hyperkinetic disorders

    L. Quintero-Giraldo, N. Gómez (Bogotá, Colombia)

  • IPX203 Achieves High Responder Rates Independent of Fluctuation Severity: Insights From RISE‑PD

    R. Hauser, J. Kopra, I. Marjanovic, G. Goisis, M. Knecht (Tampa, USA)

  • Irisin as a Molecular Mediator of Exercise Induced Neuroprotection and Disease Modification in Parkinson’s Disease

    NIK. Choudhary (Jodhpur, India)

  • Iron Dysregulation and Metabolic Inflammation in Restless Legs Syndrome: Clinical Correlates from a Tertiary hospital Cohort

    S. Shrivastava, K. Tayade, N. Rai, V. Rai (Indore, India)

  • Iron-independent initiation of neurodegeneration in BPAN

    S. Noda, N. Hattori (Bunkyo, Japan)

  • Isolated REM Sleep Behavior Disorder is Associated with Altered Nocturnal Skin Temperature Dynamics

    I. Roura, J. Pardo, C. Martín-Barceló, L. Pacheco-Jaime, C. Garcia-Vicente, C. Falcon, JA. Madrid, A. Rol, R. Sala-Llonch, M. Serradell, C. Pont-Sunyer, C. Gaig, G. Mayà, A. Montini, A. Adan, C. Junque, A. Iranzo, B. Segura (Barcelona, Spain)

  • Item – Level Drivers of Certification Failure in the MDS-UPDRS Motor Examination: A Five-Year Global Analysis

    C. Falup-Pecurariu, C. Akbostanci, E. Bayram, I. Estrada-Bellmann, J. Ma, T. Mestre, I. Murasan, O. Ojo, P. Pal, M. Qamar, F. Rodriguez-Porcel, A. Sanchez Ferro (Brasov, Romania)

  • ITSN1 Loss-of-Function variants and Parkinson’s disease risk in a Chinese cohort

    C. Li, J. Lin, Q. Jiang, J. Huang, S. Wang, X. Zheng, H. Shang (chengdu, China)

Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley